These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8910002)

  • 21. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
    Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
    J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
    Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
    Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient.
    Takahashi T; Makiguchi Y; Hinoda Y; Kakiuchi H; Nakagawa N; Imai K; Yachi A
    J Immunol; 1994 Sep; 153(5):2102-9. PubMed ID: 8051415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo.
    Mukherjee P; Ginardi AR; Tinder TL; Sterner CJ; Gendler SJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):848s-855s. PubMed ID: 11300482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines.
    Burdick MD; Harris A; Reid CJ; Iwamura T; Hollingsworth MA
    J Biol Chem; 1997 Sep; 272(39):24198-202. PubMed ID: 9305871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
    Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
    Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
    Apostolopoulos V; Xing PX; McKenzie IF
    Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
    Alajez NM; Schmielau J; Alter MD; Cascio M; Finn OJ
    Blood; 2005 Jun; 105(12):4583-9. PubMed ID: 15746083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes.
    Kontani K; Taguchi O; Narita T; Izawa M; Hiraiwa N; Zenita K; Takeuchi T; Murai H; Miura S; Kannagi R
    Br J Cancer; 2001 May; 84(9):1258-64. PubMed ID: 11336479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes.
    Ciborowski P; Konitzki WM; Blander JM; Finn OJ
    Tumour Biol; 1998; 19 Suppl 1():147-51. PubMed ID: 9422100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
    Soares M; Hanisch FG; Finn OJ; Ciborowski P
    Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.
    Hartman M; Baruch A; Ron I; Aderet Y; Yoeli M; Sagi-Assif O; Greenstein S; Stadler Y; Weiss M; Harness E; Yaakubovits M; Keydar I; Smorodinsky NI; Wreschner DH
    Int J Cancer; 1999 Jul; 82(2):256-67. PubMed ID: 10389761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
    Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
    Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
    Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
    Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.
    Vlad AM; Muller S; Cudic M; Paulsen H; Otvos L; Hanisch FG; Finn OJ
    J Exp Med; 2002 Dec; 196(11):1435-46. PubMed ID: 12461079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
    Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
    Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.